Current guidelines for treating jaundiced newborns are based on limited observational evidence most of which was acquired 3-4 decades ago. As such, evidence supporting current guidelines for jaundice management might not reflect populations cared for today, especially for premature infants. Because of conservative guidelines, close monitoring, and the availability of “safe” and effective phototherapy, acute BIND has become a rare event. Thus, the ability to evaluate new technologies aimed at improving risk assessment is limited. In this issue, Ahlfors and colleagues1 offer an approach to expand our assessment of risk within the constraints of existing guidelines.
展开▼
